Skip to content

Effect on postoperative pain and local inflammation factors PGE2 and IL-6 for total knee arthroplasty

A randomized, double-blind, RCT study of perioperative administered intravenous parecoxib: Effect on postoperative pain and local inflammation factors PGE2 and IL-6 for total knee arthroplasty

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR-TRC-10000968
Enrollment
Unknown
Registered
2010-08-09
Start date
2009-12-01
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

osteoarthritis

Interventions

1:receive parecoxib 40mg IV at the completion of surgery and 40mg iv bid for 3 days after surgery
2:receive normal saline 2ml

Sponsors

Shanghai Changzheng Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
55 Years to 75 Years

Inclusion criteria

Inclusion criteria: With Institutional Ethic Committee approval and patient's signature on consent, 100 patients will be enrolled who have an ASA physical status of I to II, between 55–75 years of age, scheduled undergoing routine total primary arthroplasty for unilateral knee with a standardized regimen of general anaesthesia.

Exclusion criteria

Exclusion criteria: Patients will be excluded who will undergo a revision to a previous TKA, emergency TKA, or TKA as a result of a trauma. Patients with a history of coagulopathy or of a thromboembolic event, serum creatinine >100 umol/L in women and >115 umol/L in men, acute infection, malignant disease, unstable angina, myocardial or cerebral infarction within 1 year prior to operation, and allergy to NSAIDs or sulphonamides. Those with inflammatory bowel disease, a chronic or acute hepatic disorder will be excluded too.

Design outcomes

Primary

MeasureTime frame
Morphine consumption;

Secondary

MeasureTime frame
Range of motion (ROM);The PGE2 and IL-6 level in drainage;VAS Pain score;

Countries

China

Contacts

Public ContactYunli Zhu
jiont-zhu@126.com+86 13386272026

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026